Author Archives: Scalper1

Buy Regional Bank ETFs Ahead Of Fed Rate Hike

The jobs report for October has greatly increased the chances of a rate hike by the Fed this year. Fed funds futures now indicate a 72% probability of a rate increase at Fed’s December meeting. As a result, investors have started positioning their portfolios for rising rates. The following 10-day chart shows rotation from rate sensitive sectors like Utilities to sectors/sub-sectors that benefit from higher rates like regional banks. Regional banks have been outperforming other financial ETFs this year and we expect this trend to continue. The banks are now well capitalized and loan growth has been picking up with improving economy. Bigger banks are most exposed to the higher regulatory costs. Capital rules now require big banks to maintain thicker capital cushions than other institutions. While higher capital norms reduce risk, they also reduce profitability. Smaller banks have simpler business models and focus on local clients and benefit from domestic economic recovery. SPDR S&P Regional Banking ETF (NYSEARCA: KRE ) is the most popular fund in the space with about $2.6 billion in AUM. PowerShares KBW Regional Banking Portfolio (NYSEARCA: KBWR ) is another interesting ETF in the space. Both these equal-weighted products currently enjoy Zacks ETF Rank # 2 (Buy). To learn more, please watch the short video below: Original Post

Starboard To Yahoo: Keep Alibaba, Sell Yahoo – Report

Yahoo (YHOO) should drop its plans to spin off its Alibaba Group (BABA) stake and instead sell its core, ailing businesses. activist investor Starboard Value said in a letter to the Internet giant, the Wall Street Journal reported Wednesday night. Starboard said the Alibaba spinoff carries too much risk, after previously supporting such a move. Earlier this year the IRS said it would not rule in advance whether the spinoff would incur billions of

KaloBios Soars 824% On Turing CEO’s Big Stock Buy

KaloBios Pharmaceuticals (KBIO) skyrocketed 824% to 19.13 in after-hours action following news that Turing Pharmaceuticals CEO Martin Shkreli bought 1.2 million shares of KaloBios. KaloBios had 4.1 million shares outstanding as of Aug. 7. Shares were bought Monday-Tuesday at prices from 61 cents to $2.43. On Friday, KaloBios said it would wind down its operations and liquidate assets. But after the Shkreli stock buy disclosure, KaloBios said an